In the Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis ( ATTEST ) , we aimed to assess the efficacy and safety of tenecteplase versus alteplase within 45 h of stroke onset in a population not selected on the basis of advanced neuroimaging , and to use imaging biomarkers to inform the design of a definitive phase 3 clinical trial .